A revolutionary new class of CNS therapeutics for a wide range of debilitating CNS disorders
Tunable and switchable
Tunable and switchable neuromodulation for personalized treatment
Oral Control | Effects managed through a specific oral medication
Tunable | Dose determines effect strength
Switchable | Stop therapy to halt all effects
Flexible Timing | Adjust treatment to match the patient's current needs
Precisely targeted
Selective targeting of a spatially and neurochemically defined neuronal population
Higher Efficacy | Direct modulation of the neurons responsible for therapeutic effects
Improved Safety | No impact on non-target neurons, reducing side effects
Customizable Reach | Modulate all neurons in the chosen area, or focus only on a defined subpopulation based on neurochemical properties
Agnoscreen™: with our proprietary platform, we can generate designer receptors from any type of GPCRs within a few months.
Our high-throughout technology allows us to screen up to 10 million receptor variants.
Around 30–40 million people live with focal epilepsy, and one in three does not respond to medication. While treatment eligibility differs among patients, all available options are highly invasive and their effectiveness varies widely, leaving most patients without a truly effective treatment.
